(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 5.7% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.94%.
Amneal Pharmaceuticals's revenue in 2024 is $2,393,607,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2024 to be $799,357,877,449, with the lowest AMRX revenue forecast at $795,018,948,819, and the highest AMRX revenue forecast at $804,683,526,282. On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $836,597,815,390, with the lowest AMRX revenue forecast at $826,646,800,481, and the highest AMRX revenue forecast at $843,191,402,753.
In 2026, AMRX is forecast to generate $866,064,952,433 in revenue, with the lowest revenue forecast at $846,018,936,376 and the highest revenue forecast at $886,110,968,491.